Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Quite, troublesome.
Which is why experienced investors buy the dips and inexperienced ones sell into them.
Simple rule: If that facts haven’t changed, don’t change your position.
All the best
Intrepid.
Agree
wrt Takeover, at the bottom of page 16 of the spreadsheet, there is an entry for "Protection from foreign takeovers", two links to the British and French Govnts providing safeguards against foreign ownership of Novacyt and other 'jewels in the crown'.
This was in response to the following last march:
Trump 'offers large sums' for exclusive US access to coronavirus vaccine
https://www.theguardian.com/us-news/2020/mar/15/trump-offers-large-sums-for-exclusive-access-to-coronavirus-vaccine
Are some of these buys from larger buyers accumulating shares
Tend to agree with you Intrepid. Too soon for takeover it will leave too much on the table. Best outcome would be several big boys (GSK, AZN,TF,Roche etc) come for us then we could top £40. With more investors in at higher prices the vote will swing away from those in at low levels. £40 is pretty good and must be very tempting to cash in your chips, the prize is much greater if we hold into Q2 2021.
Blimey troublesome thats profound. Good start today, I go back five posts and I'm at 2030 last night......get the jack plugs in the right holes.
Great post intrepid I'm now semi experienced.
Troublesome - that was poetic
@Intrepid
Lets live for today but fearless.
Some might be walking the road with a lot of trepidation after recent events.
So much of who we are is where we have been.
Intrepid Investor
I completely agree. If a takeover is avoided £200 plus is not unrealistic especially if we remain ahead of the curve with new product development.
Hi Tomozulu
I agree that a takeover is very likely. In this sort of stock, it is always possible. It’s one of the ‘risks’ insomuch that the danger is the takeover removes a large percentage of the latter-stage growth from existing SHs to in favour of the new owners. This matters because of the effects of ‘compounding interest’; if, say, the takeover is at an SP of £40, but the true value reaches £200 with 3 years, then LTHs (those in from sub £1) lose C 80% of the overall potential gains. They think they did well with c. 4000% + increases, but could have gained c. 20,000%. Means the difference between 6 figure or 7 figure gains.
The thing going in our favour is already-established strong positive cash flows (we won’t need the extra financial muscle) and no one big founder/shareholder (who can simply agree a deal and drag the rest of us along).
Let’s hope an offer does NOT materialise soon; given the antics of the last few days, I think we have far to many inexperienced SHs in our midst who would see it as a result to accept £40 now instead of £200 in 3 years.
I am serious about these ballpark figures, btw. They are now eminently achievable given Covid is here to stay over that period.
All the best
Intrepid.
I’ve been invested here for some time. I’m a veteran of healthcare investing with a few scars to show for it but some good wins too. Novacyt is different. It has a great revenue stream and really smart R and D. I guess in the long term shareholder value would be gleaned through great earnings, accretive acquisitions etc. I have thought for some time though that a bigger company will scoop this up. It will be a price that is probably sub optimal to that which would be realised if the went alone but nevertheless a very healthy price will be paid if a suitor wants to prize this away from the shareholders. I think a 2.5 bn mkt cap would be on the table.